BIO
Bio-Rad Laboratories, Inc.
BIO has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over BIO overall, supported by stronger fundamentals and stronger modeled upside.
BIO Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Healthy | |
| Strong |
BIO's cash flow and balance sheet are currently healthy, and its revenue is stable, but its profitability is under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
BIO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 4.5x | $169 | -54% |
| Fair | 7.4x | $280 | -24% |
| Current | 9.8x | $370 | — |
| Expensive | 31x | $1,157 | +212% |
| Forward | 35x | $370 | — |
Historical ranges are pointers, not guarantees.
BIO's PE is 9.8x, but its earnings don't support one, so it isn't a reliable read right now.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over BIO in the historical PE scenario, which offers more potential upside but is not a forecast.
BIO Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect BIO's earnings to grow and its profitability to improve, with its revenue holding steady.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over BIO on the outlook, with more favorable valuation and revenue expectations.
BIO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $10.69 | -72% |
| Q3 2026 | $37.91 | +$62.22 |
| Q2 2026 | $8.19 | -30% |
| Q1 2026 | $6.01 | +$82.21 |
| Q4 2025 | $27.85 | +$92.89 |
| Q3 2025 | -$24.31 | +$3.02 |
| Q2 2025 | $11.73 | +$58.76 |
| Q1 2025 | -$76.20 | -$65.84 |
| Q4 2024 | -$65.04 | -$43.55 |
BIO has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
BIO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $656.4M | +0.5% |
| Q2 2026 | $651M | -0.1% |
| Q1 2026 | $592.1M | +1.1% |
| Q4 2025 | $693.2M | +3.9% |
| Q3 2025 | $653M | +0.5% |
| Q2 2025 | $651.6M | +2.1% |
| Q1 2025 | $585.4M | -4.2% |
| Q4 2024 | $667.5M | -2% |
BIO's revenue fell from its 2020 peak and has held roughly level since: $656M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.6% | -18 points |
| Q2 2026 | 11% | -0.7 points |
| Q1 2026 | 5.8% | +1.7 points |
| Q4 2025 | -17% | -26 points |
| Q3 2025 | 10% | +0.1 points |
| Q2 2025 | 12% | -4.1 points |
| Q1 2025 | 4% | -3.3 points |
| Q4 2024 | 8.7% | -5.3 points |
BIO's operating margin was −7.6% last quarter, down 18 points from the same quarter a year ago, near the bottom of its range since 2019.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over BIO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over BIO on profitability, with a higher operating margin.
BIO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $65.2M | -27% |
| Q2 2026 | $66.7M | -5.8% |
| Q1 2026 | $78.1M | -18% |
| Q4 2025 | $119.1M | +47% |
| Q3 2025 | $89.2M | -28% |
| Q2 2025 | $70.8M | +28% |
| Q1 2025 | $95.5M | +222% |
| Q4 2024 | $81.2M | +109% |
BIO still generates free cash flow, though less than at its 2020 peak: $329M over the past year.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over BIO on cash flow, with more consistent year-over-year improvement.
BIO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +131K shares |
| 1 year | +0.1% | +22K shares |
| 3 years | -7.8% | -2.3M shares |
| 5 years | -11% | -3.3M shares |
| Available history | -11% | -3.2M shares |
BIO has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $31.5M |
| Q1 2026 | $47.8M |
| Q4 2025 | — |
| Q3 2025 | $53.4M |
| Q2 2025 | $140.2M |
| Q1 2025 | $101.9M |
| Q4 2024 | $14,000 |
BIO spent $79M buying back its own shares over the past year, down 73% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
BIO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2020 | -1.6x | Net Cash |
| Q4 2019 | -1.8x | Net Cash |
BIO has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
BIO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.1 | Neutral |
| Stochastic | 66.5 | Neutral |
BIO's weekly RSI is 59 (neutral) and its Stochastic is 67 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
BIO PE vs Healthcare Sector
| Metric | BIO | Sector median | Relative |
|---|---|---|---|
| PE | 9.8x | 26x | 62% below |
| PE % | 67 | 29 | 38 pts above |
BIO has the edge over OSCR on valuation relative to its sector.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
BIO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $370.5 | 0% below |
| 20 week MA | $355.5 | 4.2% above |
| 50 week MA | $314.3 | 18% above |
| 100 week MA | $297.5 | 25% above |
| 200 week MA | $326.1 | 14% above |
BIO has slipped below its 8-week average, but it's still above the other four, and 14% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over BIO on trend strength, trading above more of its moving averages.
BIO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $368.4 | $575.1 | +56% |
| 2021 | $575.1 | $746.3 | +30% |
| 2022 | $746.3 | $412.7 | -45% |
| 2023 | $412.7 | $322.9 | -22% |
| 2024 | $322.9 | $330.9 | +2.5% |
| 2025 | $330.9 | $303.9 | -8.2% |
| 2026 YTD | $303.9 | $370.5 | +22% |
BIO has finished lower in three of the last six years. It's up 22% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over BIO on returns for 2026, with the stronger performance.